Zika virus (ZIKV) is responsible for a massive pandemic that is associated with several devastating neuropathologic conditions, including birth defects and Guillain-Barr syndrome. There is an urgent need to understand the pathogenesis of ZIKV infections of the central nervous system (CNS) so that vaccines and therapeutics can be developed to combat ZIKV- induced CNS disease. In this application in vivo and ex vivo models of ZIKV-induced CNS pathogenesis, that have been developed in our laboratory, will be used to identify mechanisms of ZIKV CNS pathogenesis and evaluate potential therapeutic strategies for treating ZIKV- induced CNS disease. Experiments performed in Specific Aim 1 will identify ZIKV-induced CNS responses in neonatal mice and ex vivo brain slice cultures (BSCs) using an innovative genomic and bioinformatics approach, as well as by investigating the expression of specific genes and proteins and the infection and/or activation of individual CNS types. Host responses likely play a role in ZIKV-induced CNS pathogenesis and characterization and manipulation of these responses is expected to provide novel therapeutic targets for ZIKV-induced CNS disease. These therapeutic targets will be evaluated in Specific Aim 2 by determining their effect on pathogenic markers, including viral titer, cell death, tissue injury and survival. The efficacy of repurposed drugs as treatments for ZIKV-induced CNS disease will also be determined in Specific Aim 2.

Public Health Relevance

Zika virus (ZIKV) is a rapidly emerging virus that causes serious birth defects, including microcephaly, and has also been associated with Guillain-Barre syndrome (GBS), a central nervous system (CNS) disease, in adults. This application will identify host responses to ZIKV infection of the CNS and will evaluate whether manipulation of these responses, or the use of repurposed drugs, are effective treatment strategies for ZIKV-induced CNS disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21NS103186-02
Application #
9506871
Study Section
Special Emphasis Panel (ZNS1)
Program Officer
Wong, May
Project Start
2017-07-01
Project End
2019-06-30
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Pharmacology
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Messacar, Kevin; Fischer, Marc; Dominguez, Samuel R et al. (2018) Encephalitis in US Children. Infect Dis Clin North Am 32:145-162